Lupus erythematosus
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, patients diagnosed with systemic lupus erythematosus (SLE) who meet the 2019 EULAR/ACR SLE classification criteria; 2. Aged >=18 years, refer to the guidelines for the diagnosis and treatment of cutaneous lupus erythematosus (2019 edition) formulated by the Lupus Erythematosus Research Center of the Dermatology and Venereology Branch of the Chinese Medical Association, patients with clinically diagnosed cutaneous lupus erythematosus (CLE) who do not meet the 2019 EULAR/ACR SLE classification criteria; 3. Those who signed the informed consent, voluntarily accepted the treatment and were able to complete the follow-up as required.
Exclusion criteria
Exclusion criteria: 1. Associated with chronic infectious diseases (such as hepatitis B, tuberculosis, etc.), tumors, other connective tissue diseases other than lupus erythematosus, and diseases of various systems that seriously affect the quality of life of patients (except well-controlled hypertension and diabetes); 2. There are neurological, mental diseases or physical disorders (such as deafness and dumbness) that may affect the normal treatment and follow-up cooperation of patients, or in the severe active period of neurological lupus, lupus crisis and other diseases (Inclusion can be resumed after the critical period and stable condition).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue scale of disease severity self-assessment;Visual analogue scale of medical service quality survey;Treatment satisfaction questionnaire for medication;Treatment compliance;Quality of life;Emotional assessment;Adverse event; | — |
Countries
China
Contacts
Institute of Dermatology, Chinese Academy of Medical Sciences